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Abstract: Although bone marrow and bone toxicities have been reported in breast cancer survivors,
preventative strategies are yet to be developed. Clinical studies suggest consumption of long
chain omega-3 polyunsaturated fatty acids (LCn3PUFA) can attenuate age-related bone loss,
and recent animal studies also revealed benefits of LCn3PUFA in alleviating bone marrow
and bone toxicities associated with methotrexate chemotherapy. Using a female rat model for
one of the most commonly used anthracycline-containing breast cancer chemotherapy regimens
(adriamycin + cyclophosphamide) (AC) chemotherapy, this study investigated potential effects of
daily LCn3PUFA consumption in preserving bone marrow and bone microenvironment during
chemotherapy. AC treatment for four cycles significantly reduced bone marrow cellularity and
increased marrow adipocyte contents. It increased trabecular bone separation but no obvious
changes in bone volume or bone cell densities. LCn3PUFA supplementation (375 mg/100 g/day)
attenuated AC-induced bone marrow cell depletion and marrow adiposity. It also partially attenuated
AC-induced increases in trabecular bone separation and the cell sizes and nuclear numbers of
osteoclasts formed ex vivo from bone marrow cells isolated from AC-treated rats. This study suggests
that LCn3PUFA supplementation may have beneficial effects in preventing bone marrow damage
and partially protecting the bone during AC cancer chemotherapy.
Keywords: breast cancer chemotherapy; anthracycline chemotherapy; bone marrow toxicity;
marrow cellularity; marrow adiposity; bone damage; bone marrow damage; long chain omega-3
polyunsaturated fatty acids
1. Introduction
Breast cancer is known as the most frequently diagnosed cancer in women. In the past decade,
treatment for breast cancer has been transformed through changes in biological understanding and
clinical presentations of the disease. Apart from surgical treatment, hormonal therapy and radiotherapy,
the majority of patients often still require chemotherapy due to the advanced disease. There is no
doubt that earlier diagnosis with the correct use of adjuvant treatments have contributed to decreased
mortality of breast cancer survivors.
Breast cancer chemotherapy, with combination use of several different drugs, was shown to
be more effective than the use of single chemotherapy alone. One of the most commonly used
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anthracycline-containing chemotherapy regimens is adriamycin (doxorubicin) + cyclophosphamide
(AC). Although AC chemotherapy is often omitted for women with low risk node-negative breast
cancer, it is still an integral part of the adjuvant treatment for treating node-positive breast cancer.
However, despite the efficacy of AC in the treatment of breast cancer, cumulative dose during
treatment is known to cause toxicities such as bone marrow damage, cardio-toxicity or congestive
cardiomyopathy and potentially bone damage. Bone marrow toxicity or myelosuppression has been
commonly reported as the immediate and dose-limiting toxicity in breast cancer survivors. Increased
bone marrow toxicity is consistently higher with use of alkylating agents or anthracycline-based
regimens in a population-based setting [1]. In addition, bone marrow microenvironment was also
found to be severely damaged following several cycles of AC or CEF (cyclophosphamide, epirubicin
and 5-fluouracil) chemotherapy in rat models, including a severe reduction in bone marrow cellularity
and an increase in marrow adiposity [2,3]. Apart from bone marrow damage, cardio-toxicity as an
adverse effect has also been commonly reported [4]. However, there have been very few studies
addressing whether AC combination can cause bone damage as a chronic toxicity, although it was
reported that pre-menopausal women who developed ovarian failure following chemotherapy are at a
risk of rapid bone loss [5]. In addition, recent laboratory studies using female rat models also revealed
several cycles of combination chemotherapy with AC or CEF were able to induce small reductions of
trabecular bone volume within the metaphysis bone [2,3].
Since increased risk of bone marrow toxicity has been found to be consistently higher in
those receiving alkylating agents or anthracycline-based regimens [1], and anthracycline-based
combination chemotherapy continues to be the integral part of breast cancer chemotherapy due
to their treatment efficacy, it is important to not only understand the underlying mechanisms for
anthracycline chemotherapy induced-bone marrow/bone defects, but also to develop potential
strategies for protecting bone marrow and bone during breast cancer chemotherapy. Long chain
omega-3 polyunsaturated fatty acids (LCn3PUFA), including eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA), are known to have various health benefits including prevention of
cardiovascular diseases and promoting bone health [6]. The health benefits of LCn3PUFA are mainly
due to their anti-inflammatory actions. Clinically, a promising association between LCn3PUFA intake
and improved bone mineral density has been reported in some studies [7]. Consumption of LCn3PUFA
has also been shown to attenuate age-related bone loss [8,9]. Furthermore, animal studies reported that
dietary LCn3PUFA supplementation can enhance bone mass and bone formation in ovariectomized
rats [10], as well as protecting bone and bone marrow during short-term methotrexate (MTX)
chemotherapy in young rats [11,12]. However, it is not known whether LCn3PUFA supplementation
can also protect bone and bone marrow during AC chemotherapy.
Due to some similarities in bone/bone marrow outcomes and in some cellular processes
(including increased osteoclastogenesis, oxidative stress and bone marrow adipogenesis and decreased
osteogenesis) between postmenopausal osteoporosis and cancer chemotherapy-induced bone/marrow
damages [11,13–15], we hypothesized that LCn3PUFA supplementation, which has shown benefits
in protecting bone and bone marrow as reported in the above recent clinical and animal studies,
may also have some efficacy in alleviating bone/bone marrow damage caused by combination
breast cancer chemotherapy. Using a rat model, the current study addressed whether daily
LCn3PUFA supplementation could help to alleviate bone marrow and bone damage during AC
combination chemotherapy.
2. Results
2.1. Treatment Effects on Body Weight Changes
Overall, rats from all treatment groups appeared to be healthy and gained weight constantly
throughout the trial, although the AC alone group failed to gain weight at a rate of the control rats
following the third of 4 cycles of AC treatment (Figure 1) (p > 0.05). Interestingly, when comparing
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both water gavage and LCn3PUFA gavage control groups, rats gavaged with LCn3PUFA appeared to
gain more weight when compared to saline control. Similarly, in both groups receiving AC treatment,
starting from day 12, AC + LCn3PUFA-treated rats appeared to have a slightly higher weight gain
when compared to AC-alone treated rats (p > 0.05).
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2.2. Treatment Effects on Bone Marrow Microenvironment
As a means to evaluate treatment-induced bone marrow damage or potential protection, this
study also examined treatment effects on overall bone marrow microenvironment and cellularity.
Our ex vivo counting of non-adherent bone marrow cells isolated from the AC-treated rats revealed a
significant drop in bone marrow cells when compared to the control (p < 0.05) (Figure 2A). Consistently,
from histological analyses of haematoxylin and eosin (H&E)-stained tibia sections, this study also
observed an obvious trend of depletion of bone marrow cells following 4 cycles of AC treatment
within the lower secondary spongiosa when compared to normal control rats (p > 0.05) (Figure 2B–E).
The depletion of bone marrow cells was accompanied by a significant increase in marrow adipocyte
contents (p < 0.01) (Figure 2B–D,F).
In rats receiving daily LCn3PUFA supplementation during AC treatment, bone marrow cellularity
had a trend of improvement when compared to AC treatment alone (p > 0.05) as revealed by ex vivo cell
counting (Figure 2A) and by histological analyses (p > 0.05) (Figure 2E). Furthermore, daily LCn3PUFA
supplementation during AC treatment suppressed AC-induced increase in marrow adipose content to
a level that was comparable to that of control rats (p > 0.05) (Figure 2F).
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pointing to adipocytes. Scale bar on all panels = 200 µm. Treatment effects on the marrow cellularity 
(%) (E) and marrow adiposity % (F). Significant values are indicated as: * p < 0.05 and ** p < 0.01 
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computed tomography (µ-CT) 3D analyses were conducted on the region 0–2 mm below the growth 
plate, consisting of mainly primary and secondary spongiosa (regions rich in bone trabeculae)  
(Figure 3A). Although µ-CT analyses revealed no significant changes in trabecular bone volume 
across all treatment groups (p > 0.05) (Figure 3A,B), some trabecular structural changes were 
observed. A trend of reduction in trabecular number (p > 0.05) and a significant increase in trabecular 
spacing were observed in AC alone-treated group when compared to the control group (p < 0.05) 
(Figure 3C–E). LCn3PUFA supplementation did not affect AC treatment-induced trabecular 
structural changes (p > 0.05) (Figure 3C–E). 
Figure 2. Effects of daily omega-3 polyunsaturated fatty acid (PUFA) supplementation during
weekly AC treatment on bone marrow constitution. Treatment effects on counts of bone marrow
non-adherent cells isolated from treated rats (A); Haematoxylin and eosin (H&E)-stained sections of
the lower secondary spongiosa region of the tibia from a control rat (B); an AC-treated rat (C) and an
AC + PUFA-treated rat (D); with yellow arrows pointing to non-fat cell bone marrow cells, red arro s
pointing to adipocytes. Scale bar on all panels = 200 µm. Treatment effects on the marrow cellularity (%)
(E) and marrow adiposity % (F). Significant values are indicated as: * p < 0.05 and ** p < 0.01 compared
t control.
2.3. Treatment Effects on Overall Trabecular Bone Volume and Structures in the Metaphysis
To examine treatment effects on overall trabecular bone volume and structural changes,
micro-computed tomography (µ-CT) 3D analyses were conducted on the region 0–2 mm below the
growth plate, consisting of mainly primary and secondary spongiosa (regions rich in bone trabeculae)
(Figure 3A). Although µ-CT analyses revealed no significant changes in trabecular bone volume
across all treatment groups (p > 0.05) (Figure 3A,B), some trabecular structural changes were observed.
A trend of reduction in trabecular number (p > 0.05) and a significant increase in trabecular spacing
were observed in AC alone-treated group when compared to the control group (p < 0.05) (Figure 3C–E).
LCn3PUFA supplementation did not affect AC treatment-induced trabecular structural changes
(p > 0.05) (Figure 3C–E).
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osteoclasts. Counting of tartrate-resistant acid phosphatase-positive (TRAP+) multinucleated 
osteoclasts on the trabecular surface revealed no significant overall changes in the osteoclast density 
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showed a statistically non-significant trend of being able to lower the osteoclast density when 
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Figure 3. Effects of daily omega-3 polyunsaturated fatty acid (3PUFA) supplementation during weekly
AC treatment on metaphyseal trabecular bone volume and structure. µ-CT longitudinal cross-section
of a control rat tibia (A); Region within the red dotted line (region of interest) represents the first 2 mm
of metaphysis fro the end of growth plate, where all µ-CT scan data were analysed. Analyses of the
treatment effects on trabecular bone volume/tissue volume (BV/TV) (B) and trabecular structures
including trabecular number (C); trabecular thickness (D) and trabecular spacing (E).
2.4. Treatment Effects on Bone Cells at the Metaphysis
To analyse the potential cellular basis that may contribute to the bone changes observed following
treatments, bone cell densities were examined. Firstly, since BLCs are more abundant than the bone
forming osteoblasts in skeletally mature rats, this study examined the treatment effects on densities
of bone lining cells (BLCs). BLCs, that appear flattened and extended over trabecular surface, are
the inactive forms of osteoblasts and are responsible for protection of the bone surface (Figure 4A),
and can be induced to proliferate and differentiate into osteogenic cells [16]. Histological analyses
of H&E-stained slides revealed no significant changes of BLC densities across all treatment groups,
suggesting treatments had no effect on bone surface protection against external factors which may
induce bone damage (Figure 4B).
Apart from osteogenic cells, this study also examined treatment effects on bone resorptive
cells osteoclasts. Counting of tartrate-resistant acid phosphatase-positive (TRAP+) multinucleated
osteoclasts on the trabecular surface revealed no significant overall changes in the osteoclast density
between all treatment groups. However, daily LCn3PUFA supplementation during AC treatment
showed a statistically non-significant trend of being able to lower the osteoclast density when compared
to AC alone-treated rats (p > 0.05) (Figure 4C–E).
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Figure 4. Effects of daily omega-3 polyunsaturated fatty acid (3PUFA) supplementation during weekly
AC treatment on bone cells at primary spongiosa. H&E stained metaphysis of a control rat (A); with
arrows pointing to bone lining cells. Analyses of the treatment effects on bone lining cell density
(B); Tartrate-resistant acid phosphatase (TRAP)-stained tibia sections of an AC-treated rat (C) and
AC + PUFA-treated rat (D); with arrows pointing to multinucleated osteoclasts. Treatment effects on
osteoclast density (E). Scale bar on all panels A, C and D = 50 µm.
2.5. Treatment Effects on Ex Vivo Osteoclast Formation Potential
In order to examine whether treatments can have an effect on osteoclast formation potential from
the bone marrow cells, an ex vivo formation assay was performed using bone marrow cells obtained
from treated rats. In consistency to our histological findings, the ex vivo osteoclast formation assay
also revealed no changes in osteoclast formation potential between all treatment groups (Figure 5A–C).
Interestingly, however, the sizes of osteoclasts formed from bone marrow of AC-treated rats were
significantly larger when compared to the control rats (p < 0.05) (Figure 5D), while osteoclasts formed
from the marrow cells of AC + LCn3PUFA rats were similar in size to those formed from bone marrow
cells of control rats (Figure 5B,D). Furthermore, AC alone-treated rats were found to have significantly
more nuclei within the osteoclasts when compared to osteoclasts formed from the bone marrow of
control rats (Figure 5E). However, the changes observed in both osteoclast size and nuclei number in
AC-treated rats were attenuated by LCn3PUFA supplementation (p < 0.05) (Figure 5D,E). These results
suggest that, although LCn3PUFA supplementation had no effects on ex vivo osteoclast formation
potential, it can reduce the size of osteoclasts formed and the number of nuclei within osteoclasts
during AC treatment.
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3. Discussion
Combination chemotherapy has been shown to be more effective in breast cancer treatment
when compared to single agent used alone. However, women receiving combination treatment
experienced more adverse effects. Chemotherapeutics such as taxane, adriamycin, 5-fluorouracil,
cyclophosphamide, methotrexate, and cisplatin are known to cause an increase in bone resorption
independent of bone metastasis and a deterioration in bone structure [17]. Adriamycin is a common
anthracycline agent that is used widely in treating both early and late stage metastatic breast cancer.
A clinical report indicated that premenopausal breast cancer patients treated with AC combination
resulted in a lower bone mineral density and significant bone loss [18]. Animal studies have also
reported that adriamycin exposure caused a reduction in bone formation due to reduced osteoblast
differentiation [19], and can negatively affect bone trabecular microarchitecture and mechanical
properties [20]. Using a rat AC treatment model mimicking the clinical setting, our recent animal study
also revealed that 4 cycles of AC treatment were able to cause severe bone marrow damage and some
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reduction in trabecular bone volume [2]. Since anthracycline-based combination chemotherapy remains
to be the backbone for treating breast cancer nowadays, it is vital to develop preventive strategies for
alleviating bone marrow and bone toxicities that may affect quality of life post chemotherapy. Recently,
several nutraceuticals (including LCn3PUFA) have been found to have some efficacies to promote
bone health under physiological conditions or during methotrexate chemotherapy [21]. Consumption
of LCn3PUFA has been suggested to attenuate aging-related bone loss and preventing bone loss
in ovariectomized models [8,10]. In addition, daily LCn3PUFA supplementation at 375 mg/100 g
body weight during short-term methotrexate chemotherapy was able to preserve bone formation,
suppress bone resorption and marrow adiposity in young rats [11,12]. However, no previous studies
have determined whether LCn3PUFA supplementation during anthracycline-based combination
chemotherapy can maintain bone health in breast cancer survivors. Using a rat AC treatment model
mimicking the clinical setting [2], the current study revealed that daily LCn3PUFA supplementation
can protect against AC-induced bone marrow damage.
In the current study as well as in the previous study [2], rats were intravenously injected with
the combination of 20 mg/kg cyclophosphamide and 2 mg/kg adriamycin once weekly for 4 weeks,
dosages of which were similar to those converted from clinical doses in humans (cyclophosphamide
600 mg/m2 and adriamycin 60 mg/m2 for a total of 4 cycles). In addition, considering differences
in drug metabolism rates between rats and humans, the dosages and the timing of dosing used in
the current and the previous study [2] had also been adjusted basing on previous rat studies using
these drugs [22,23], and basing on another AC model in female rats (used to study cardiotoxicity) in
which the drugs were dosed once weekly for 4 weeks at similar but slightly higher doses (40 mg/kg
cyclophosphamide + 3 mg/kg adriamycin) [24]. The current study revealed that rats were overall
healthy in all treatment groups, despite a slight decrease in body weight gain after 3 cycles of AC
treatment in AC alone group, which is consistent with the previous study [2]. Interestingly, starting
from day 12, AC + LCn3PUFA-treated rats appeared to have a slightly higher weight gain when
compared to AC-alone treated rats, suggesting potential benefits of LCn3PUFA in promoting overall
health during AC chemotherapy.
Examination of the bone marrow environment in the current study revealed dramatic changes
following 4 cycles of AC treatment. These changes include the depletion of bone marrow cells.
Clinically, bone marrow suppression following cancer treatment is frequently reported, while some
patients are known to have acute myelosuppression, others who receive chemotherapy and/or ionizing
radiation may experience irreversible chronic bone marrow injuries [25]. A higher risk of bone marrow
toxicity has also been reported in patients who received anthracycline-based regimens irrespective
of the treatment cycles [1]. A significant limitation of the current study is that our data derived
from ex vivo cell counting and histological examination have only indicated a decrease in bone
marrow cell numbers or cellularity following AC treatment. Further studies will be required to
investigate how AC chemotherapy impact on hematopoietic stem/progenitor cells and their clonogenic
regeneration capacities.
Accompanying the myelosuppression discussed above is the increased marrow adiposity with
significant infiltration of adipocytes, a phenomenon also commonly observed in cancer patients
following irradiation or chemotherapy [26,27]. These findings are consistent with previous animal
studies which reported treatments with methotrexate alone or CEF or AC combination were able to
induce bone marrow toxicity in rats [2,3,28]. While mechanisms for the marrow injuries following
chemotherapy are yet to be fully elucidated, one study has shown that the attenuated Wnt/β-catenin
signaling in the bone may be mediating the enhanced bone marrow adipocyte accumulation following
methotrexate treatment [29]. In addition, one study suggests that the phenomenon of bone marrow
adiposity coupled with myelosuppression may be due to the imbalance between leptin, growth
hormone/insulin-like growth factor and estrogen axis [30]. Further studies are required to examine
whether these possibilities also apply in the AC chemotherapy setting.
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Furthermore, it has also been suggested that bone marrow adipocytes do not just simply
fill the marrow space but can act as negative regulators of the bone marrow microenvironment.
Evidence has shown that adipocytes/stromal cells have direct functions on hematopoietic cells
through their production of cytokines and adipokines, such as IL-6, TNF-α, and adiponectin
which inhibit hematopoietic proliferation and activity, therefore negatively regulate bone marrow
microenvironment [31,32]. In a mouse study, when arabinosylcytosine-C chemotherapy-induced
adipogenesis was inhibited using an inhibitor, accelerated recovery of leukocyte counts, increased
colony forming units and Ki67+Lin−Sca1+c-kit+ bone marrow cell population were observed [33],
suggesting hematopoietic recovery is improved following arabinosylcytosine-C chemotherapy when
adipogenesis was inhibited. However, the relationship between increased marrow adiposity and
hematopoiesis still warrants further investigation following AC chemotherapy.
Our study also revealed that LCn3PUFA supplementation was able to partially prevent bone
marrow damage from AC chemotherapy, as shown by the bone marrow cellularity recovery and
reduced marrow adiposity. The benefits of LCn3PUFA in promoting hematopoiesis has also been
reported in other animal studies. One study revealed that chronic intake of a LCn3PUFA-rich diet
increases the abundance of hematopoietic stem cells in both bone marrow and spleen, in part via the
activity of matrix metalloproteinase 12 [34]. Another study revealed that LCn3PUFA supplementation
can restore rosiglitazone-induced bone marrow adiposity by suppressing pro-inflammatory cytokines
and promoting anti-inflammatory cytokines [35]. Furthermore, LCn3PUFA supplementation can
suppress methotrexate chemotherapy-induced bone marrow adiposity in young rats by suppressing
adipocyte differentiation and expression of adipogenic genes PPARγ and FABP4 [12]. Overall, findings
from this study and previous animal studies suggest daily LCn3PUFA supplementation may promote
hematopoiesis while suppressing bone marrow adiposity that is known to negatively regulate bone
marrow microenvironment under different circumstances. However, while the LCn3PUFA alone
treatment showed a statistically non-significant trend of increasing bone marrow cellularity and
decreasing adipocyte contents in control rats, and while the AC treatment had more substantial and
statistically significant effects on bone marrow cellularity and in adiposity (opposite to effects of AC),
we cannot rule out the possibility that the simple combination of these opposite effects (of AC and
LCn3PUFA) may have contributed to the outcomes seen in the AC + LCn3PUFA group. Further studies
are required to investigate the mechanisms for these treatment effects.
It is generally believed that the clinical observations of bone loss are primarily in post-menopausal
women or in premenopausal women made amenorrheic by chemotherapy. It has been reported that
women receiving anthracycline-based chemotherapy suffer from chemotherapy-induced amenorrhea
and cause bone loss [36,37]. In postmenopausal patients who have progressive bone loss due to
natural ovarian failure and aging, it has been also reported that adjuvant chemotherapy exacerbates
estrogen deficiency, contributing to increased osteoporosis [38]. Furthermore, while accelerated bone
loss can result from cancer treatment-induced endocrine defects [39], evidence has emerged and is
emerging that breast cancer chemotherapy itself may also directly damage bone. A recent rat AC
treatment model also in intact female rats has demonstrated that AC treatment can damage bone [2],
and previous studies have shown that various cancer drugs including adriamycin, cyclophosphamide,
5-fluorouracil, and methotrexate individually or in combination (e.g., with CEF) can directly damage
bone cells and interfere with bone formation [3,28,40–43]. Since cancer drugs can damage normal bone
cells and bone regardless, and AC chemotherapy is given to both pre- and post-menopausal women,
the current study has used an AC chemotherapy model in adult intact female rats. Furthermore,
while further studies are required to examine whether AC chemotherapy can alter serum estrogen
levels in treated rats, a recent rat CEF study showed that 6 cycles of CEF treatment only slightly and
insignificantly reduced serum estrogen levels although the treated rats suffered from a significant loss
of trabecular bone in tibia [3].
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Clinical studies have reported that AC chemotherapy has negative impact on bone mineral
density and can cause significant bone loss at several sites [18,44]. Our recent animal study also
revealed significant trabecular bone loss with changes in trabeculae structures following 4 cycles of
AC chemotherapy [2]. In the current study, no significant changes were observed in overall bone
volume between all treatment groups. Interestingly, trabeculae structure examination revealed that
the trabecular number was reduced following AC treatment, which was accompanied by increase in
trabecular thickness and spacing, and a trend of statistically nonsignificant reduction in trabecular
bone volume. These changes in trabecular structures were consistent with our previous findings [2].
Animal studies have reported that several cycles of combination chemotherapy involving the
use of anthracyclines can negatively affect bone remodeling by either reducing numbers of bone
surface lining cells (BLC) or promoting osteoclast formation or osteoclastic resorption [2,3]. The current
study revealed no significant changes in densities of bone lining cells and osteoclasts following four
cycles of AC treatment. However, despite the insignificant changes, the current study observed
that LCn3PUFA supplementation appeared to have a trend to lower bone lining cell densities in
both control and in AC-treated animals, the mechanism for which requires further investigation.
In addition, a trend of osteoclast density reduction was observed in rats that received LCn3PUFA
supplementation during AC treatment, suggesting daily LCn3PUFA intake may be able to suppress
bone resorption during AC chemotherapy. The benefits of LCn3PUFA in reducing bone resorption in
alleviating chemotherapy-induced bone damage has also been previously revealed both in clinical and
animal studies [12,45]. It is suggested that LCn3PUFA can inhibit osteoclast formation through their
anti-inflammatory properties [45], such as suppressing the mRNA expression of pro-osteoclastogenic
and pro-inflammatory cytokines including RANKL receptor activator of nuclear factor kappa B (NF-κB)
ligand], tumor necrosis factor-α (TNF-α), interleukin-6 (IL-1), and IL-6 [12].
In consistency with our histological findings, our ex vivo osteoclast formation assays revealed no
significant changes in osteoclast formation potential of bone marrow cells across all treatment groups.
However, the osteoclast size and the number of nuclei within osteoclasts were significantly increased
in osteoclasts formed from bone marrow cells of AC-treated rats when compared to control, which
was consistent with previous studies that reported bigger osteoclasts with more nuclei being formed
from bone marrow cells of rats following several cycles of breast cancer AC or CEF chemotherapy [2,3].
Interestingly, osteoclasts formed ex vivo were found smaller in size and with fewer nuclei from
the marrow cells of rats which received LCn3PUFA supplementation during AC treatment. It is
known that osteoclast size and their nuclei numbers are positively associated with bone resorption
potential and activity [46,47]. Therefore, our ex vivo data indirectly suggest that daily LCn3PUFA
supplementation may attenuate osteoclast resorbing activity during breast cancer chemotherapy. In
support of our ex vivo findings, one study reported that a LCn3PUFA diet was able to suppress
the increased activity and number of osteoclasts in ovariectomized rats by suppressing activation of
osteoclastogenesis transcription factor NF-κB, and subsequent downregulation of osteoclastogenic
cytokines TNF-α, macrophage colony-stimulating factor (M-CSF), and RANKL [48]. Another animal
study also revealed that daily LCn3PUFA supplementation can suppress methotrexate-induced
expression of osteoclastogenesis-related cytokines and modulate inflammatory mediators, therefore
suppressing bone resorption [12]. Although our results did not show a significant reduction in overall
bone volume, it is possible that other breast cancer chemotherapy regimens may cause more severe
damage to the bone by promoting more bone resorption, hence LCn3PUFA supplementation may still
offer its therapeutic benefits in preventing bone loss during breast cancer chemotherapy.
The dose of LCn3PUFA given to the rats (3.75 g/kg/day, equivalent to consuming 0.5 mL/100 g/day)
is high when compared to the recommended 3.4 g DHA + EPA/day for a 50–70 kg human, but is
consistent with the typical efficacious dose for anti-inflammatory and cardiovascular benefits in
numerous rodent studies. While further studies are needed to define the minimal effective dose of
LCn3PUFA for protecting bone marrow and bone during AC chemotherapy for rats and humans, this
dose was adopted from previous rat studies wherein LCn3PUFA supplementation during short-term
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methotrexate chemotherapy was able to preserve bone formation, suppress bone resorption and
marrow adiposity in young rats [11,12], and emu oil at 1 mL/100 g/day was able to prevent 5-fluouracil
chemotherapy-induced bone loss [49].
4. Materials and Methods
4.1. Animal Trial
Female Sprague-Dawley rats of twelve-weeks old were randomly allocated into four groups
(Table 1) receiving oral gavage of water or LCn3PUFA (ROPUFA® 75-EE, an ethyl ester derivation from
fish oil containing 42% EPA and 22% DHA) (DSM Nutritional Products, Kaiseraugst, Switzerland)
at 0.5 mL/100 g/day (equivalent to consuming 375 mg of LCn3PUFA/100 g/day) [12]. After one
week of pre-treatment, rats were intravenously injected with sterile water or the combination of AC
once weekly for 4 weeks, comprising of 20 mg/kg cyclophosphamide (Baxter, Deerfield, IL, USA)
and 2 mg/kg adriamycin (Ebewe, Unterach, Austria). Dosage chosen for cyclophosphamide and
adriamycin were based on our previous study [2]. Daily oral gavage of water or LCn3PUFA continued
throughout the trial and ended 1 day before specimen collection. By the end of fourth cycle, rats
were euthanized by CO2 overdose and different specimens were collected for analysis. The animal
procedures described above were approved by the Animal Ethics Committee of the SA Pathology
(South Australia), Animal Ethics Approval Number: 129f 10 (approval date: 17 July 2013).
Table 1. List of treatment groups for the animal trial.
Groups Injection Gavage
Control (n = 6) Sterile water Sterile water
LCn3PUFA (n = 6) Sterile water LCn3PUFA
AC (n = 8) AC Sterile water
AC + LCn3PUFA (n = 8) AC LCn3PUFA
LCn3PUFA, omega-3 polyunsaturated fatty acids; AC, adriamycin + cyclophosphamide chemotherapy.
4.2. Specimen Collection
Both hind limbs were dissected and cleaned free of soft tissue. Left tibias were fixed in 10%
formalin for 24 h, transferred to 70% ethanol for storage until ready for µ-CT analyses (see below).
Tibias were wrapped in saline-soaked gauze prior to conducting µ-CT scanning. Following µ-CT,
tibias were decalcified in Immunocal (Decal Corporation, Tallman, NY, USA) at 4 ◦C, processed
and embedded in paraffin for 4 µm sectioning for histological analyses (see below). The right
tibias and femurs and two front limbs were used to obtain bone marrow cells for isolation of bone
marrow mononuclear cells (BMMNCs) using Lymphoprep [28]. BMMNCs were then plated and
cultured overnight for the isolation of non-adherent haematopoietic cells for osteoclast formation assay
(see below) [11].
4.3. Ex Vivo µ-CT
Trabecular bone volume and structures were assessed using the µ-CT scanner (Skyscan 1174,
Kontich, Belgium). Briefly, trabecular bone region from 0–2 mm below the growth plate was selected
for bone measurement analyses, which include trabecular bone volume/total volume ratio (BV/TV
%), trabeculae thickness (mm), trabeculae number (per mm) and trabecular spacing (mm) [3].
4.4. Histological Analysis
Tibial paraffin sections (4 µm thick) were de-waxed and stained with H&E for analyses of bone
lining cells, bone marrow adipocytes and bone marrow cellularity as described [42]. Sections were also
stained with TRAP for the analyses of osteoclast density. To examine the effects of daily LCn3PUFA
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supplementation during AC chemotherapy on bone cells, densities of both bone lining cells (BLCs)
and osteoclasts were measured along the trabeculae surface within the primary spongiosa. To examine
the treatment effects on overall changes in the bone marrow, in the lower secondary spongiosa region
(marrow rich area with areas containing haematopoietic cells), adipocytes were traced and scored as a
percentage of total marrow area [50].
4.5. Ex Vivo Osteoclast Formation Assay
To assess the effects of daily LCn3PUFA supplementation during AC chemotherapy on the
ability of osteoclast formation, an ex vivo osteoclast formation assay was performed. Briefly, bone
marrow non-adherent cells were cultured overnight at 1.5 × 105 cells/well in 96-well plate in basal
medium supplemented with 10 ng/mL M-CSF (Peprotech, Rocky Hill, NJ, USA), followed by culturing
in medium containing 10 ng/mL M-CSF and 30 ng/mL RANKL (Peprotech, Rocky Hill, NJ, USA).
Culture was maintained for 8 days with M-CSF+RANKL medium changed every 3 days, and cells were
fixed on day 9 for TRAP staining to identify osteoclasts. Apart from osteoclast density measurement,
the average osteoclast size and number of nuclei per osteoclast were also determined as described [50].
4.6. Statistical Analysis
All results are presented as the means ± the standard error of the mean (SEM) and were analysed
by non-parametric Kruskal-Wallis test. When significance (p < 0.05) was reached, the post hoc Dunn’s
multiple comparison test was performed with GraphPad Prism 7 software (GraphPad Software Inc.,
Lo Jolla, CA, USA). In data graphs, * and ** above each bar indicate significance compared to the control
group, and # and ## above horizontal bars reflect differences between connected groups. Significant
values are indicated as: * or # = p < 0.05 and ** or ## = p < 0.01.
5. Conclusions
This study has examined the effects of dietary LCn3PUFA supplementation on long bones of rats
subjected to 4 cycles of AC breast cancer chemotherapy. This study observed that 4 cycles of AC breast
cancer chemotherapy increased trabecular bone separation. Although weekly AC treatment in this
study did not cause a significant decrease in the overall bone volume or bone cell density, ex vivo results
revealed increased osteoclast size and nuclear numbers in osteoclasts formed, indirectly suggesting an
increased bone resorption potential following AC treatment. However, bone marrow was found more
severely damaged following AC treatment, as indicated by depletion of bone marrow cells and an
increase in marrow adiposity. Daily LCn3PUFA supplementation during AC chemotherapy maintained
the bone marrow microenvironment by preserving bone marrow cellularity and suppressing marrow
adiposity, and it was able to preserve the trabecular bone microstructure (Figure 6). Thus, LCn3PUFA
supplementation showed promising effects in preventing AC chemotherapy-induced bone marrow
damage, suggesting its therapeutic potential in alleviating marrow damage caused by breast cancer
chemotherapy. We cannot exclude the possibilities that other breast chemotherapy regimens may
induce more severe damage to both bone marrow and bone, hence further studies should be carried
out with different breast cancer chemotherapy models. In addition, different doses of LCn3PUFA
supplementation need to be examined to reveal the optimal dose required to relieve bone marrow and
bone toxicities associated with breast cancer chemotherapy regimens.
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